Nycomed

NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

www.nycomed.com

Nycomed RSS Channel

Display # 
Title Published Date
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 18 January 2012
Nycomed reports double-digit growth across emerging markets in second quarter 2011 17 August 2011
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets 16 June 2011
Nycomed continues to outperform in emerging markets in first quarter 2011 26 May 2011
Nycomed acquires distribution rights to product portfolio in Turkey 14 April 2011
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment 31 March 2011
Nycomed well positioned in emerging markets 02 March 2011
Nycomed's novel COPD therapy roflumilast receives FDA approval 01 March 2011
Nycomed to acquire Colombian company Farmacol 06 February 2011
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 06 January 2011
Nycomed is keeping the pace in third quarter 2010 10 November 2010
Nycomed to accelerate expansion in China 01 November 2010
Global market launch of Daxas® (Roflumilast) kicks off in Germany 01 September 2010
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 07 July 2010
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® 03 May 2010
Nycomed and Baxter receive FDA approval for TachoSil® 08 April 2010
Nycomed on track in 2009 with strong growth in Key Products 02 March 2010
Nycomed reports continued satisfactory performance in the third quarter 2009 13 November 2009
Nycomed reports sustained momentum in second quarter 2009 20 August 2009
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD 11 August 2009

Most Popular Now

New particle can track chemo

Tracking the path of chemotherapy drugs in real time and at a cellular level could revolutionize cancer care and help doctors sort out why two patients might respond diff...

Read more

The effects of the Trans-Pacific Pa…

The Trans-Pacific Partnership (TPP) is a multi-national trade agreement now being considered by 12 countries. In an insightful commentary in Research in Social and Admini...

Read more

Global pharmaceutical industry call…

More than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on govern...

Read more

Human medicines: highlights of 2015

The European Medicines Agency (EMA) has released an overview of its 2015 key recommendations in relation to the marketing authorisations of new medicines and the safety m...

Read more

Merck announces new biopharma heads…

Merck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's bio...

Read more

Leading medical journals propose ma…

The International Committee of Medical Journal Editors (ICMJE) proposes new rules that will require authors to share clinical trial data as a prerequisite for their manus...

Read more

Boehringer Ingelheim and Arena Phar…

Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an ...

Read more

Merck launches Vivera in Latin Amer…

Merck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in...

Read more

New drug could be safer, non-addict…

Researchers at Tulane University and Southeast Louisiana Veterans Health Care System have developed a painkiller that is as strong as morphine but isn't likely to be addi...

Read more

European Commission confirms CMDh r…

The European Commission (EC) has taken an EU-wide legally binding decision and confirmed the favorable benefit/risk profile of ambroxol and bromhexine containing medicine...

Read more

FDA approves first drug to show sur…

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue...

Read more

Ancient medicinal clay shows promis…

Naturally occurring clay from British Columbia, Canada - long used by the region's Heiltsuk First Nation for its healing potential - exhibits potent antibacterial activit...

Read more

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]